Browse Negotiations Image Banner

Banner Text Velit velaliquam, ultricies eros dolore magna in in doming ullamco sint. Sint doming dignissim in quis pariatur consequat urna eu providerent. Sint dolore ea urna velit doming ea pulvinar.

General Callout

Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.

Accordion

Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.

Heading 1

Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.

Heading 2

Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.

Related content

Dolor commodo suscipit adipiscing suscipit, elit dolore velit. Amet tempuribud velit pariatur ullamco exercitation esse dolore sint velaliquam adipiscing eu pulvinar doming sunt, dignissim velit voluptate ex suscipit sunt ex, duis dignissim nunc tempuribud laboris commodo velit ut. Velit in harmud quis voluptate esse nulla.

Shop Now!

Laboris quis consectetur sed eros velit tempuribud suscipit magna ea consequat laboris. Elit adipiscing quis sunt duis magna nulla velit amet elit ex providerent consectetur tempuribud amet ex commodo urna, magna adipiscing elit sed duis nisi pulvinar, doming pariatur velaliquam quis providerent fugiat ea aliquip sit ut nisi sunt pulvinar eu velit.

grey rec centre

Call to action

Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate

Primary Button Secondary Button

Search by drug, manufacturer, or indication

Displaying 781 - 790 of 1165

Dupixent (dupilumab)

Status:

Concluded with an LOI

Manufacturer:

Sanofi Genzyme Canada

Indication:

Atopic dermatitis

Last updated September 17, 2019

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)

Status:

Concluded with an LOI

Manufacturer:

GlaxoSmithKline Inc.

Indication:

Chronic Obstructive Pulmonary Disease (COPD)

Last updated September 9, 2019

Opdivo (nivolumab)

Status:

Concluded with an LOI

Manufacturer:

Bristol Myers Squibb Canada Inc.

Indication:

Melanoma adjuvant therapy

Last updated September 6, 2019

Alunbrig (brigatinib)

Status:

Negotiations were not pursued

Manufacturer:

Takeda Canada Inc.

Indication:

Non-Squamous Non-Small Cell Lung Cancer

Last updated September 5, 2019

Tafinlar/Mekinist (dabrafenib/trametinib)

Status:

Concluded with an LOI

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Indication:

Melanoma adjuvant therapy

Last updated August 30, 2019

Unituxin (dinutuximab)

Status:

Concluded with an LOI

Manufacturer:

United Therapeutics

Indication:

Neuroblastoma

Last updated August 30, 2019

Zirabev (bevacizumab)

Status:

Concluded with an LOI

Manufacturer:

Pfizer Canada ULC

Indication:

Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer

Last updated August 28, 2019

Monoprost (latanoprost)

Status:

Concluded without agreement

Manufacturer:

Laboratoires Thea

Indication:

Glaucoma and Ocular Hypertension

Last updated August 28, 2019

Imfinzi (durvalumab)

Status:

Concluded with an LOI

Manufacturer:

AstraZeneca Canada Inc.

Indication:

Non-small Cell Lung Cancer

Last updated August 26, 2019

Cystadrops (cysteamine)

Status:

Concluded with an LOI

Manufacturer:

Recordati Rare Diseases Canada Inc.

Indication:

Corneal cystine crystal deposits

Last updated August 22, 2019